Product
rMenB+OMV NZ
1 clinical trial
2 indications
Indication
MeningitisIndication
MeningococcalClinical trial
A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of KoreaStatus: Not yet recruiting, Estimated PCD: 2026-04-10